DISCO制药公司与安进签署独家许可协议，推进针对表面组的癌症疗法-动脉网

DISCO Pharmaceuticals and Amgen Ink Exclusive License Deal to Advance Surfaceome-Targeted Cancer Therapies

GeneOnline 等信源发布 2026-01-07 11:18



可切换为仅中文







by Richard Chau

作者：周理查德

Share To

分享到

DISCO Pharmaceuticals has entered an exclusive license agreement with US biopharma giant Amgen to advance cancer therapeutic programs. The German biotech stands to receive up to $618 million in aggregate payments and future royalties. (Image: 123RF)

DISCO制药公司已与美国生物制药巨头安进达成独家许可协议，以推进癌症治疗项目。这家德国生物技术公司预计将获得总计高达6.18亿美元的付款和未来特许权使用费。（图片来源：123RF）

erman biotech DISCO Pharmaceuticals has entered an exclusive license agreement with US biopharma giant

德国生物技术公司DISCO制药已与美国生物制药巨头签订独家许可协议

Amgen

安进公司

to advance therapeutic programs directed at a cancer cell surface target identified by DISCO’s proprietary surfaceome-mapping technology.

推进针对由DISCO专有的表面组学图谱技术识别的癌细胞表面靶点的治疗计划。

Under the agreement

根据协议

with undisclosed upfront payment, Amgen obtains exclusive global rights to develop and commercialize programs directed against the surfaceome target mapped by DISCO, while DISCO stands to receive up to $618 million in aggregate payments and future royalties tied to development and commercial milestones..

通过未公开的预付款，安进公司获得了针对由DISCO定位的表面组靶点开发和商业化项目的全球独家权利，而DISCO则有可能获得高达6.18亿美元的总付款以及与开发和商业里程碑相关的未来特许权使用费。

The Cologne-based pharmaceutical research company expects that the proceeds of the licensing deal will enable them to advance multiple lead antibody-drug conjugate (ADC) candidates in small cell lung cancer (SCLC) and microsatellite-stable colorectal cancer (MSS-CRC) toward IND-enabling studies and expand its pipeline..

这家总部位于科隆的制药研究公司预计，授权交易的收益将使他们能够推动多个小细胞肺癌（SCLC）和微卫星稳定型结直肠癌（MSS-CRC）的先导抗体药物偶联物（ADC）候选药物进入支持新药临床试验（IND）的研究，并扩展其研发管线。

What DISCO’s Platform Brings to the Table

DISCO平台带来的优势

The

surfaceome

表面组学

(or cell surface proteome) refers to the complete set of proteins located on the outer surface (plasma membrane) of a cell that are exposed to the extracellular environment. These proteins act as receptors, transporters, enzymes, and structural components involved in cell communication, immune response, and the regulation of transport across the cell membrane, thus playing the “gatekeeping roles” for various vital cellular processes..

（或细胞表面蛋白质组）指的是位于细胞外表面（质膜）上暴露于细胞外环境的全部蛋白质。这些蛋白质充当受体、转运蛋白、酶和结构成分，参与细胞通讯、免疫反应以及跨细胞膜运输的调节，从而在各种关键细胞过程中发挥“把关作用”。

DISCO’s value proposition rests on a surfaceome mapping platform that combines cell-surface proteomics with advanced protein-community mapping to identify previously inaccessible target pairs and surface-bound protein communities. This pioneering approach is designed to reveal

DISCO的价值主张基于一个表面组学映射平台，该平台结合了细胞表面蛋白质组学与先进的蛋白质群落图谱技术，以识别以前无法获取的靶标对和表面结合的蛋白质群落。这种开创性的方法旨在揭示

indication-specific and pan-tumor opportunities

特定适应症和泛肿瘤机会

that are difficult to detect with conventional target-discovery methods, and to guide the design of bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) with high specificity. From the company’s perspective, the deal is a validation that surfaceome mapping can uncover clinically actionable cell-surface targets suitable for next-generation therapeutic modalities..

这些目标难以用常规的靶点发现方法检测，并引导设计具有高特异性的双特异性抗体药物偶联物（ADC）和T细胞接合器（TCE）。从公司的角度来看，这笔交易验证了表面组学图谱能够揭示适用于下一代治疗模式的临床可操作细胞表面靶点。

DISCO’s Pipeline Focus and Near-term R&D Priorities

DISCO的管道聚焦与近期研发重点

DISCO’s publicly stated internal pipeline is focused on hard-to-treat solid tumors including SCLC and MSS-CRC, and the company says its first ADC programs are advancing toward the clinic. The license to Amgen pertains to a different, platform-derived target mapped on the cancer surfaceome. The current agreement gives Amgen the right to progress programs against that target through clinical development and commercialization. .

DISCO公司公开表示，其内部研发管线专注于难治性实体瘤，包括小细胞肺癌（SCLC）和微卫星稳定型结直肠癌（MSS-CRC），并称其首个抗体药物偶联物（ADC）项目正在向临床推进。授权给安进（Amgen）的许可涉及一个不同的、基于平台衍生的癌症表面组学靶点。根据当前协议，安进有权针对该靶点推进项目进入临床开发和商业化阶段。

For this reason, the transaction represents both a near-term validation event for DISCO’s discovery capabilities and a pathway to leverage Amgen’s development resources and global commercialization infrastructure for specific assets. “Joining forces with a recognized global leader in advancing innovative cancer treatments underscores the potential inherent in our technology to go beyond traditional cancer targets to deliver novel impactful medicines for high need cancer indications,” said DISCO’s CBO Ajla Hrle..

出于这个原因，这笔交易既是对DISCO发现能力的近期验证事件，也是利用安进的开发资源和全球商业化基础设施来推进特定资产的一条途径。DISCO首席业务官阿依拉·赫尔勒表示：“与公认的全球先进创新癌症治疗领导者携手，凸显了我们的技术超越传统癌症靶点、为高度需求的癌症适应症提供新颖且有影响力的药物的潜力。”

Strategic Rationale for Amgen and Implications for DISCO

安进的战略理由及对DISCO的影响

For Amgen, the deal is consistent with an established external innovation strategy: licensing differentiated discovery platforms or early-stage assets that fill gaps in its oncology portfolio. Surfaceome-guided targets and bispecific modalities remain an active area of interest for large oncology developers because of their potential to improve therapeutic index and tumor selectivity. .

对于安进公司而言，这笔交易与其既定的外部创新战略一致：授权引入差异化的发现平台或早期资产，以填补其肿瘤学产品组合中的空白。由于表面组引导的靶点和双特异性模式具有提高治疗指数和肿瘤选择性的潜力，它们仍然是大型肿瘤开发商关注的活跃领域。

For DISCO, partnering with a large, experienced oncology developer accelerates the probability that a platform-derived discovery can reach patients, while allowing DISCO to capture upside via milestones and royalties without bearing the full cost of late-stage development. According to

对于DISCO而言，与一家大型且经验丰富的肿瘤学开发商合作，可以加速平台衍生的发现成果惠及患者的概率，同时让DISCO能够通过里程碑付款和特许权使用费获得收益，而无需承担后期开发的全部成本。根据

Mark Manfredi, Ph.D.,

马克·曼弗雷迪，博士，

DISCO’s newly-appointed CEO

DISCO新任命的首席执行官

, this agreement “demonstrates the potential of our surfaceome mapping platform technology to uncover cancer cell surface targets with meaningful clinical potential.” He also expressed his optimism that the collaboration with Amgen will enable the company to translate their biological insights into innovative therapies which may deliver better outcomes for patients..

，该协议“展示了我们表面组学绘图平台技术在发现具有重要临床潜力的癌细胞表面靶点方面的潜力。”他还表示乐观地认为，与安进的合作将使公司能够将其生物学见解转化为创新疗法，从而为患者带来更好的治疗效果。

Dr. Manfredi’s remarks reflect continuity with the strategy he outlined upon his CEO appointment and the company’s recently closed €36 million seed financing round, which is intended to advance lead ADC programs toward IND-enabling studies.

曼弗雷迪博士的言论反映了他被任命为首席执行官时所概述的战略的连续性，以及公司最近完成的3600万欧元种子融资回合，该资金旨在推动主要ADC项目向可申请新药临床试验方向发展。

Scientific and Commercial Context: Why Surfaceome Discovery Matters

科学与商业背景：为什么表面组发现很重要

Target discovery that focuses on the surfaceome has gained traction because it directly supports modalities that need extracellular access (ADCs, bispecific antibodies, TCEs). By mapping the composition and communities of proteins on the tumor cell surface, companies aim to identify target combinations that improve tumor selectivity or enable novel mechanisms such as conditional activation. .

靶点发现聚焦于表面组学（surfaceome）已受到关注，因为它直接支持需要细胞外访问的治疗模式（如抗体药物偶联物、双特异性抗体、T细胞接合器）。通过绘制肿瘤细胞表面蛋白质的组成和群落图谱，公司旨在识别提高肿瘤选择性的靶点组合或启用诸如条件性激活等新机制。

If DISCO’s platform consistently yields targets with robust biology and acceptable safety windows, the model of early discovery followed by out-licensing to a development partner could be a repeatable commercialization route. That potential explains why Amgen, a company with deep expertise in both antibody therapeutics and late-stage development, would take an exclusive license rather than relying solely on internal discovery..

如果DISCO的平台能够持续产生具有强大生物学依据且安全性窗口可接受的靶点，那么早期发现后将其授权给开发合作伙伴的模式可能成为一条可重复的商业化路径。这种潜力也解释了为什么在抗体治疗和后期开发方面都拥有深厚专业知识的安进公司会选择获得独家许可，而不是仅仅依赖内部发现。

Merck Strikes $1.3 Billion Deal to Acquire Curon’s B-Cell Therapy Drug

默克公司达成13亿美元协议收购Curon的B细胞治疗药物

Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals

2024年生物技术行业趋势：数十亿美元的肿瘤学交易概览

Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights

罗氏获得人工智能血糖监测解决方案的CE认证，通过预测性洞察提升糖尿病护理水平。

Strategic Outsourcing: How CDMO Partnerships Are Tipping the Scales from Cost Efficiency to Supply Chain Resilience

战略外包：CDMO合作伙伴关系如何从成本效益转向供应链弹性

Amgen Acquires Teneobio to Snag New Class of Antibody Therapies

安进收购Teneobio以获取新型抗体疗法

Navigating the Valley of Death: How Biotech Startups Can Survive Venture Capital Realities